Hemeteam has six parts.

1: Hematopoiesis and related topics
2: Disease of hematopoiesis
3: Molecularly targeted therapy
4: Bleeding and clotting
5: Approach to common problems
6: Case studies

Hemeteam is free of charge and advertising, and the author has no conflicts of interest.

You may freely use The QxMD Hematology calculator which has many interesting applications.

by Peter R. Galbraith MD, FRCP(C) Last edited Mar 29, 2013

Welcome to HemeTeam 2013

HemeTeam is a companion to hematological studies, designed to present a succinct account of what is new and important for students and physicians.

These notes on the pathogenesis, manifestations and treatment of common blood diseases, are frequently updated to reflect the advances.

The incorporation of molecular genetic data into clinical trials has elevated therapeutics to a whole new level of sophistication. We still need to keep things in perspective, with these important advances in mind.

Perhaps the most important advance in hematology is the recognition of the prime importance of the supportive tumour cell microenvironment such as in multiple myeloma, and the need to target it in refractory cases of chronic lymphocytic leukemia. The microenvironment has been relatively neglected in diseases such as peripheral T-cell lymphoma which are associated with a poor prognosis.

There are some case studies with MCQs and feedback.

To Navigate: Use the links on this page.

Your browser's back (or forward) arrow bring you back to this page. The EXIT button exits HemeTeam.

Contents

Part 1. Hematopoiesis and related topics

Part 2. Diseases of Hematopoiesis:

a) Anemia and some cases

b) Stem cells

c) Lymphocytes

Part 3. Molecularly Targeted Therapy

Part 4. Bleeding and Clotting

Part 5. Approach to common problems

Part 6. Case studies again repeated here for convenience

You may freely use The QxMD Hematology Calculator which has many interesting uses.